Share on LinkedInShare on LinkedIn

ARTICLE · 13 MAY 2024

Historic Shift In U.S. Drug Policy: DEA Proposes To Reclassify Marijuana

Lowenstein Sandler LLP
Lowenstein Sandler LLP
Contributor
Lowenstein Sandler LLP

Lowenstein Sandler LLP

Lowenstein Sandler LLP is a national law firm with over 400 lawyers based in New York, Palo Alto,...

View firm profile
Explore more from Lowenstein Sandler LLP

The U.S. Drug Enforcement Administration (DEA) is on the brink of reclassifying marijuana, marking a watershed moment in American drug policy.

United StatesCannabis & Hemp

The U.S. Drug Enforcement Administration (DEA) is on the brink of reclassifying marijuana, marking a watershed moment in American drug policy.

For decades, marijuana has been classified as a Schedule I drug, alongside substances like heroin, ecstasy, and LSD, under the Controlled Substances Act. The proposed reclassification of marijuana from Schedule I to Schedule III represents a shift in federal drug policy. Schedule I substances are classified as drugs with a high potential for abuse and no currently accepted medical use in the United States. In comparison, oxycodone and fentanyl, which have accepted medical uses, are only Schedule II substances (i.e., drugs with a high potential for abuse). Schedule I substances are considered to be the most dangerous and tightly controlled under the Controlled Substances Act.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from